1. Field of the Invention
This invention relates generally to the transdermal electrokinetic mass transfer of medication into a diseased tissue, and, more specifically, to a medicament containing iontophoresis electrode for the delivery of medication across the skin and into diseased tissues and blood vessels adjacent to the delivery site.
2. Prior Art
Iontophoresis has been employed for several centuries as a means for applying medication locally through a patient's skin and for delivering medicaments to the eyes and ears. The application of an electric field to the skin is known to greatly enhance the skin's permeability to various ionic agents. This permeability change has been used, for example, to enhance transcutaneous transport of glucose for monitoring blood glucose levels. The use of iontophoretic transdermal delivery techniques has obviated the need for hypodermic injection for many medicaments, thereby eliminating the concomitant problems of trauma, pain and risk of infection to the patient.
Iontophoresis involves the application of an electromotive force to drive or repel oppositely charged ions through the dermal layers into a target tissue. Particularly suitable target tissue include tissues adjacent to the delivery site for localized treatment or tissues remote therefrom in which case the medicament enters into the circulatory system and is transported to a tissue by the blood. Positively charged ions are driven into the skin at an anode while negatively charged ions are driven into the skin at a cathode. Studies have shown increased skin penetration of drugs at anodic or cathodic electrodes regardless of the predominant molecular ionic charge on the drug. This effect is mediated by polarization and osmotic effects.
Regardless of the charge of the medicament to be administered, a iontophoretic delivery device employs two electrodes (an anode and a cathode) in conjunction with the patient's skin to form a closed circuit between one of the electrodes (referred to herein alternatively as a “working” or “application” or “applicator” electrode) which is positioned at the delivered site of drug delivery and a passive or “grounding” electrode affixed to a second site on the skin to enhance the rate of penetration of the medicament into the skin adjacent to the applicator electrode.
Recent interest in the use of iontophoresis for the transdermal delivery of drugs to a desired cutaneous or subcutaneous treatment site has stimulated a redesign of many of such drugs with concomitant increased efficacy of the drugs when delivered transdermally. As iontophoretic delivery of medicaments become more widely used, the opportunity for a consumer/patient to iontophoretically self-administer a transdermal dosage of medicaments simply and safely at non-medical or non-professional facilities would be desirable and practical. Similarly, when a consumer/patient travels, it would be desirable to have a personal, easily transportable apparatus available which is operable for the iontophoretic transdermal delivery of a medication packaged in a single dosage applicator. A problem which presents an impediment to potential users is the necessity for reformulating medicaments for iontophoretic delivery. Such reformulations must be approved by cognizant regulatory agencies prior to sale. This requires delay and additional expense for the manufacturer, which additional expense may be passed along to consumers. The present invention provides a disposable medicament dispensing electrode for use with a portable iontophoretic medicament delivery apparatus in which the electrode is adapted for use with the apparatus for self-administering medicament. The medicament dispensing portion of the electrode can accept, store and dispense presently approved medicament formulations.
The present invention discloses a unit dosage medicament applicator electrode adapted for use with a portable iontophoretic transdermal or transmucoscal medicament delivery apparatus for the self-administration of a unit dose of a medicament into the skin. The electrode and current supply apparatus is particularly suited for the localized treatment of herpes infections. The established treatment for recurrent genital herpetic lesions has been primarily supportive; including local topical application of anesthesia. Severe cases have been treated with systemic Acyclovir®, Zovirax® (Glaxo-Wellcome) or Famvir® (SmithKline Beecham). Some cases the condition is managed with prophylactic long-term dosing administration with a suitable antiviral agent at great expense. Systemic treatment of acute herpetic flare-ups may reduce the normal 10-12 day course of cutaneous symptoms into a 6-8 day episode. Topical treatment of lesions with Acyclovir® has not been as effective as in vitro studies would suggest. A compound which is not presently available to clinicians but has demonstrated significant anti herpetic activity is 5-iodo-2 deoxyuridine (IUDR). Both of those agents have shown limited clinical efficacy when applied topically to the herpetic lesion. It is the present inventor's contention that the limited efficacy of topical administration previously observed is, at least in part, due to the poor skin penetration of these medicaments when applied topically. The present invention discloses a mesh-like iontophoresis electrode, which contains and dispenses pre-approved formulations of those medicaments and provides improved transdermal delivery of these medicaments.
Genital herpes (usually herpes simplex II infection) afflicts many people, cause discomfort, shame, and may contribute to more severe and costly illnesses such as cervical cancer, prostate cancer, and perinatal blindness from herpetic conjunctivitis. Certain formulations containing anti-viral and/or anti-microbial drugs have been approved for topical application by the cognizant regulatory agency. Reformulation of such compositions for iontophoretic transdermal drug delivery entails significant delays before such technology is available to the public for general use. The present invention discloses a medicated iontophoresis electrode for the portable transdermal delivery of Acyclovir® (9-[(2-hydroxyethoxy)methyl]guanine) or similar anti-viral agent formulations which have already received (or may in the future receive) regulatory approval to greatly benefit these afflicted patients. In a second preferred embodiment of the invention, the medicament delivery electrode is attached to a user-wearable glove having one or more fingers or merely a finger cot covering at least a portion of one or more fingers of a user's hand.
It is an object of the present invention to provide an iontophoretic medicament delivery electrode which is adapted to be used with an iontophoresis device operable for self-administration of medicament into the skin of a person.
It is another object of the present invention to provide an improved iontophoretic transdermal drug delivery apparatus having a medicament-containing application electrode which disperses a single dosage and is disposable and non-reusable.
It is a further object of the present invention to provide an iontophoresis electrode meeting the above objectives which can receive and retain a previously approved drug formulation for dispensation by ionosonic transdermal delivery. It is still another advantage of the present invention to provide an improved disposable iontophoretic medicament applicator which meets the above objectives and which is inexpensive, safe to use and greatly increases the therapeutic efficacy of a medicament administered thereby.
The medicament-containing electrode in accordance with the present invention, together with an iontophoresis apparatus, provides a means for transdermally administering medicament dispersed in a variety of previously approved formulations directly and with high efficiency into a diseased tissue thereby providing a novel method for treating clinical conditions presenting mucocutaneous symptoms and particularly mucocutaneous Herpes Simplex viral eruptions and sequelle associated therewith.
The above objects, features and advantages of the invention are realized by the improved monopolar iontophoretic medicament applicator electrode. The objects, features and advantages of the invention will become apparent upon consideration of the following detailed disclosure of the invention, especially when it is taken in conjunction with the accompanying drawings wherein:
The applicator electrode 10 comprises a substantially flat elongate strip having lateral ends extending from a central portion. The central medicament dispensing portion 12 is of mesh-like construction and has vertical cells dimensioned to accommodate a viscous fluid within the confines of the cellular structures. The viscous fluid contained within each of the plurality of cells 12a includes a medicament (not shown) which is in a form suitable for transport under the influence of an electrical current. The lateral ends of the applicator electrode 10 include a mesh-like tactile conductive portion 11 which contains an electrically conductive gel therewithin. The applicator electrode 10 has an upper skin-facing surface 13 and a lower, device-facing surface 14. One or a plurality of cells 12a form one or a plurality of apertures between the upper skin-facing surface 13 and the lower device-facing surface 14. The device-facing surface 14 may further include an adhesive layer 18 applied thereto suitable for releasably adhering the applicator electrode 10 to the positive (anode) or negative (cathode) pole of a iontophoresis handpiece. The positioning of the electrode's tactile conductive portion 11 on the surface of the handpiece is such that tactile conductive portion 11 makes electrical contact with the tactile electrode 42 on the handpiece. When the applicator electrode 10 is correctly positioned on the handpiece, the medicament dispensing reservoir 12 is in electrical communication with the electrically contacting element 41 on the handpiece. In addition, one or more small magnets 15 may positioned on the handpiece to activate a switch within said handpiece which turns the handpiece on and/or off. The relatively narrow, flexible areas 16 on the electrode enable the applicator electrode 10 to be bent and formed around the handpiece.
Turning next to
A bottom view of the applicator electrode of
Turning now to
The simple design is capable of retaining and dispensing existing medicament formulations and the size of the retaining cells 72 in the mesh portion of the electrode may be varied. The structural matrix of the applicator electrode is a flexible hypoallergenic, non-electrically-conductive material. A suitable material is Silastic®, a silicone elastomer which is biocompatible, non-conductive, flexible and possessing sufficient structural rigidity to contain medicaments and a delivery vehicle within the retaining cells 114. Further, Silastic silicone elastomer is inert so that medicaments will not oxidize or otherwise have their chemical structures damaged. An electrode constructed from silicone elastomer has a prolonged shelf-life, is soft and pleasant on contact, is hypoallergenic and sufficiently flexible to adhere to any anatomical contour such as presented by a thimble. Such anatomical plasticity is a key advantage to the foregoing design. Other polymers, such as polyurethane, are suitable as well. A hydrated hydrophilic cotton layer (not shown) may be interposed between the medicament dispensing portion 71 and the electrically conductive surface 41 of the handpiece 40 to provide pretreatment hydration of the medicament dispensing portion or the mesh may be hydrated by the patient immediately prior to use.
With reference to the embodiment of an iontophoresis applicator electrode shown in FIGS. 7,9, the electrode is easily manufactured using mold technology wherein uncured silicone elastomer is either poured into a complementary mold or pressure-mold injected. The lower surface 74 of the non-medicament dispensing portion of the electrode is coated with skin adhesive. The medicament dispensing portion 71 functions as a medicament reservoir and is preferably between 1 mm and 4 mm thick, depending upon the amount of medicament required to be stored in the cells 72. The medicament-retaining cells 72, which are preferably a hexagonal, honey comb-like structure, retain the medicament therein through their surface tension. Hexagonal cells also lessen cross channel conductivity by means of their vertical orientation. The size and geometry of these cells can vary. The smallest cells, for instance, would be more suited to retaining liquid medicaments while the larger cells are better adapted to retain ointment-based medicaments. Medium cells are more suited to retaining and dispensing gel medicaments and lotions. The silicone walls of the cells can be chemically modified to change the hydrophobic surface characteristics thereof and further improve retention of specially formulated liquid medicaments. For additional cell stability and retention capabilities, the skin-facing surface of the cells can be covered with non-wicking, fibrous and porous materials commonly used in electrodes. A composite or unitary construction from a single mold can be used depending on production cost, it is inexpensive to manufacture and it offers both a compartment for storage of existing formulations as well as a structural backbone for the application electrode. The surface treatments of the retaining material bounding each of the cells to create hydrophilic or hydrophobic surface effects depending on the formulation to be utilized is well known in the art. An example of such technology is disclosed, for example, in U.S. Pat. No. 5,589,563. For ointments and hydrophobic materials, silicone is preferred. For water or gel medicaments, surface treatment such as doping the elastomeric cell surface with hydrophilic molecules can be of additional benefit, as described herein. The embodiments disclosed herein present the following advantages:
Inexpensive manufacture;
Use of either injection or pour molding production;
Use of composite sheet cutout assembly;
Anatomically conforming;
Elastomer surface modification for optimum retention of medicament;
Variable retaining cell size;
Variable retaining cell geometry;
Ability to utilize existing medicament formulations;
May use a cotton or (other hydrophilic matrix) layer for rapid pre-treatment hydration.
May be used with single or multi-channel dispersive iontophoretic drivers; and
May be used with iontophoretic or ionosonic devices.
An embodiment of the present invention adapted for delivering medicament to a large area of skin is shown in FIG. 13. The iontophoresis electrode is contained within a glove adapted to conform to and be worn upon a patient's hand. The glove embodiment 130 of the iontophoresis drug delivery electrode comprises an elastomeric glove 131 having a plurality of holes or open pores 132 in the palmar surface 133 thereof Underlying the palmar surface 133 and disposed within the glove between the skin 134 and glove is an electrically insulating sheet 135 having an inner surface 136 and an outer surface 137, both of which surfaces are coated with an electrically conductive layer 138. The inner conductive layer 136 is, in use, in electrical communication with the skin. The outer conductive layer 137 is in contact with the interior surface of the glove and the pores 132. A medicament 139 capable of iontophoretic transdermal delivery is contained within the pores. A bipolar power source 140 has a working electrode 141 in electrical communication with the outer conductive layer 137 coating the electrically insulating sheet 135, and a ground electrode (not shown) which is in electrical communication with the inner conductive layer coating the electrically insulating sheet. When the power source 140 is energized, an electrical current flows between the inner conductive layer and the outer conductive layer, which layers are separated by the electrically insulating sheet, via the patient's skin. The polarity and amplitude of the current flowing through pores into the user's skin facilitates entry of the medicament into the skin. The glove embodiment, shown in use in
The advantages of a unitary iontophoresis electrode and a glove and finger cot embodiment of an iontophoresis electrode for drug delivery have been presented. It is noted that similarly constructed electrodes may be employed for non-invasively collecting molecular species from the blood. For example, the mesh may be impregnated with an electrically conductive gel. The polarity of the gel, with respect to the skin, may be employed to transport blood components through the skin into the gel where such components may be detected and/or quantitated. Such measurements are useful for monitoring blood levels of compounds such as glucose or drugs.
While the invention has been described above with references to specific embodiments thereof, it is apparent that many changes, modifications and variations in the materials, arrangements of parts and steps can be made without departing from the inventive concept disclosed herein. For example, an impregnated conductive gel can also be used to as medicament containing medium to increase the physical stability and the tissue adhering characteristics of the electrode. Accordingly, the spirit and broad scope of the appended claims is intended to embrace all such changes, modifications and variations that may occur to one of skill in the art upon a reading of the disclosure. All patent applications, patents and other publication cited herein are incorporated by reference in their entirety.
This application is a continuation of application Ser. No. 09/653,992, filed Sep. 1, 2000 abandoned, which in turn was a divisional of application Ser. No. 09/153,640, filed Sep. 15, 1998, now U.S. Pat. No. 6,148,231, issued Nov. 14, 2000, the disclosures of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
206474 | Morel | Jul 1878 | A |
279524 | Beaty | Jun 1883 | A |
484522 | McBride | Oct 1892 | A |
600290 | Muir | Mar 1898 | A |
1967927 | Deustch | Jul 1934 | A |
2047308 | Chapman | Jul 1936 | A |
2123980 | Warwick | Jul 1938 | A |
2126070 | Wappler | Aug 1938 | A |
2834344 | Kanai | May 1958 | A |
3019787 | Simmons | Feb 1962 | A |
3048170 | Lemos | Aug 1962 | A |
3107672 | Hofmann | Oct 1963 | A |
3163166 | Brant et al. | Dec 1964 | A |
3298368 | Charos | Jan 1967 | A |
3520297 | Bechtold | Jul 1970 | A |
3556105 | Shepard | Jan 1971 | A |
3645260 | Cinotti et al. | Feb 1972 | A |
3716054 | Porter et al. | Feb 1973 | A |
3831598 | Tice | Aug 1974 | A |
3848600 | Patrick, Jr. et al. | Nov 1974 | A |
4116238 | Pettijohn | Sep 1978 | A |
4166457 | Jacobsen et al. | Sep 1979 | A |
4211222 | Tapper | Jul 1980 | A |
4292968 | Ellis | Oct 1981 | A |
4301794 | Tapper | Nov 1981 | A |
4325367 | Tapper | Apr 1982 | A |
4383529 | Webster | May 1983 | A |
4393884 | Jacobs | Jul 1983 | A |
4406658 | Lattin et al. | Sep 1983 | A |
4416274 | Jacobsen et al. | Nov 1983 | A |
4429703 | Haber | Feb 1984 | A |
4474570 | Ariura et al. | Oct 1984 | A |
4510939 | Brenman et al. | Apr 1985 | A |
4639244 | Rizk et al. | Jan 1987 | A |
4655229 | Sensabaugh, Jr. et al. | Apr 1987 | A |
4665921 | Teranishi et al. | May 1987 | A |
4689039 | Masaki | Aug 1987 | A |
4702732 | Powers et al. | Oct 1987 | A |
4708716 | Sibalis | Nov 1987 | A |
4735217 | Gerth et al. | Apr 1988 | A |
4747819 | Phipps et al. | May 1988 | A |
4756318 | Clearman et al. | Jul 1988 | A |
4763660 | Kroll et al. | Aug 1988 | A |
4764164 | Sasaki | Aug 1988 | A |
4767402 | Kost et al. | Aug 1988 | A |
4771796 | Myer | Sep 1988 | A |
4776353 | Lilja et al. | Oct 1988 | A |
4786278 | Masaki | Nov 1988 | A |
4787888 | Fox | Nov 1988 | A |
4793366 | Hill | Dec 1988 | A |
4800903 | Ray et al. | Jan 1989 | A |
4808152 | Sibalis | Feb 1989 | A |
4813437 | Ray | Mar 1989 | A |
4820263 | Spevak et al. | Apr 1989 | A |
4821740 | Tachibana et al. | Apr 1989 | A |
4838273 | Cartmell | Jun 1989 | A |
4865582 | Sibalis | Sep 1989 | A |
4907606 | Lilja et al. | Mar 1990 | A |
4913148 | Diethelm | Apr 1990 | A |
4917119 | Potter et al. | Apr 1990 | A |
4919648 | Sibalis | Apr 1990 | A |
4922901 | Brooks et al. | May 1990 | A |
4931046 | Newman | Jun 1990 | A |
4942883 | Newman | Jul 1990 | A |
4950229 | Sage, Jr. | Aug 1990 | A |
4953565 | Tachibana et al. | Sep 1990 | A |
4957480 | Morenings | Sep 1990 | A |
4979938 | Stephen et al. | Dec 1990 | A |
4997418 | DeMartini | Mar 1991 | A |
5002527 | Reller et al. | Mar 1991 | A |
5006108 | LaPrade | Apr 1991 | A |
5019034 | Weaver et al. | May 1991 | A |
5037381 | Bock et al. | Aug 1991 | A |
5042975 | Chien et al. | Aug 1991 | A |
5047007 | McNichols et al. | Sep 1991 | A |
5053001 | Reller et al. | Oct 1991 | A |
5060671 | Counts et al. | Oct 1991 | A |
5090402 | Bazin et al. | Feb 1992 | A |
5115805 | Bommannan et al. | May 1992 | A |
5133352 | Lathrop et al. | Jul 1992 | A |
5135478 | Sibalis | Aug 1992 | A |
5135479 | Sibalis et al. | Aug 1992 | A |
5147291 | Cukier | Sep 1992 | A |
5160316 | Henley | Nov 1992 | A |
5162042 | Gyory et al. | Nov 1992 | A |
5167242 | Turner et al. | Dec 1992 | A |
5169384 | Bosniak et al. | Dec 1992 | A |
5171215 | Flanagan | Dec 1992 | A |
5203768 | Haak et al. | Apr 1993 | A |
5250022 | Chien et al. | Oct 1993 | A |
5254081 | Maurer et al. | Oct 1993 | A |
5279543 | Glikfeld et al. | Jan 1994 | A |
5284471 | Sage, Jr. | Feb 1994 | A |
5298017 | Theeuwes et al. | Mar 1994 | A |
5310404 | Gyory et al. | May 1994 | A |
5312326 | Myers et al. | May 1994 | A |
5314502 | McNichols et al. | May 1994 | A |
5331979 | Henley | Jul 1994 | A |
5354321 | Berger | Oct 1994 | A |
5360440 | Andersen | Nov 1994 | A |
5362307 | Guy et al. | Nov 1994 | A |
5362308 | Chien et al. | Nov 1994 | A |
5374241 | Lloyd et al. | Dec 1994 | A |
5374242 | Haak et al. | Dec 1994 | A |
5376107 | Inagi et al. | Dec 1994 | A |
5391195 | Van Groningen | Feb 1995 | A |
5395310 | Untereker et al. | Mar 1995 | A |
5413590 | Williamson | May 1995 | A |
5415629 | Henley | May 1995 | A |
5421816 | Lipkovker | Jun 1995 | A |
5441936 | Houghten et al. | Aug 1995 | A |
5443441 | De Claviere | Aug 1995 | A |
5458569 | Kirk, III et al. | Oct 1995 | A |
5464387 | Haak et al. | Nov 1995 | A |
5466217 | Myers et al. | Nov 1995 | A |
5470349 | Kleditsch et al. | Nov 1995 | A |
5494679 | Sage, Jr. et al. | Feb 1996 | A |
5501705 | Fakhri | Mar 1996 | A |
5514167 | Smith et al. | May 1996 | A |
5538503 | Henley | Jul 1996 | A |
5540669 | Sage, Jr. et al. | Jul 1996 | A |
5551953 | Lattin et al. | Sep 1996 | A |
5558632 | Lloyd et al. | Sep 1996 | A |
5562607 | Gyory | Oct 1996 | A |
5589563 | Ward et al. | Dec 1996 | A |
5603693 | Frenkel et al. | Feb 1997 | A |
5607461 | Lathrop | Mar 1997 | A |
5607691 | Hale et al. | Mar 1997 | A |
5618275 | Bock | Apr 1997 | A |
5658247 | Henley | Aug 1997 | A |
5667487 | Henley | Sep 1997 | A |
5668170 | Gyory | Sep 1997 | A |
5676648 | Henley | Oct 1997 | A |
5678273 | Porcelli | Oct 1997 | A |
5688233 | Hofmann et al. | Nov 1997 | A |
5697896 | McNichols et al. | Dec 1997 | A |
5700457 | Dixon | Dec 1997 | A |
5711761 | Untereker et al. | Jan 1998 | A |
5713846 | Bernhard et al. | Feb 1998 | A |
5722397 | Eppstein | Mar 1998 | A |
5725817 | Milder | Mar 1998 | A |
5733255 | Dinh et al. | Mar 1998 | A |
5755750 | Petruska et al. | May 1998 | A |
5788666 | Atanasoska | Aug 1998 | A |
5794774 | Porcelli | Aug 1998 | A |
5795321 | McArthur et al. | Aug 1998 | A |
5797867 | Guerrera et al. | Aug 1998 | A |
5830175 | Flower | Nov 1998 | A |
5840057 | Aloisi | Nov 1998 | A |
5846217 | Beck et al. | Dec 1998 | A |
5865786 | Sibalis et al. | Feb 1999 | A |
5879323 | Henley | Mar 1999 | A |
5882676 | Lee et al. | Mar 1999 | A |
5899875 | Millot | May 1999 | A |
5899876 | Flower | May 1999 | A |
5908401 | Henley | Jun 1999 | A |
5911319 | Porcelli et al. | Jun 1999 | A |
5919155 | Lattin et al. | Jul 1999 | A |
5931859 | Burke | Aug 1999 | A |
5935598 | Sage et al. | Aug 1999 | A |
5954684 | Flower et al. | Sep 1999 | A |
5961482 | Chien et al. | Oct 1999 | A |
5961483 | Sage et al. | Oct 1999 | A |
5968005 | Tu | Oct 1999 | A |
5968006 | Hofmann | Oct 1999 | A |
5983130 | Phipps et al. | Nov 1999 | A |
6004309 | Phipps | Dec 1999 | A |
6004547 | Rowe et al. | Dec 1999 | A |
6006130 | Higo et al. | Dec 1999 | A |
6018679 | Dinh et al. | Jan 2000 | A |
6023639 | Hakky et al. | Feb 2000 | A |
6032073 | Effenhauser | Feb 2000 | A |
6038485 | Axelgaard | Mar 2000 | A |
6041252 | Walker et al. | Mar 2000 | A |
6041253 | Kost et al. | Mar 2000 | A |
6048545 | Keller et al. | Apr 2000 | A |
6057374 | Huntington et al. | May 2000 | A |
6101411 | Newsome | Aug 2000 | A |
6148231 | Henley | Nov 2000 | A |
6148232 | Avrahami | Nov 2000 | A |
6167302 | Millot | Dec 2000 | A |
6267736 | McCambridge | Jul 2001 | B1 |
6385487 | Henley | May 2002 | B1 |
6477410 | Henley et al. | Nov 2002 | B1 |
Number | Date | Country |
---|---|---|
OE 0232642 | Mar 1964 | AT |
0230749 | Aug 1987 | EP |
0309093 | Mar 1989 | EP |
617979 | Oct 1994 | EP |
1445703 | Jun 1966 | FR |
2 513 129 | Mar 1983 | FR |
0299553 | Nov 1928 | GB |
3-170172 | Jul 1991 | JP |
654254 | Mar 1979 | SU |
931191 | May 1982 | SU |
1003853 | Mar 1983 | SU |
8607269 | Dec 1986 | WO |
WO 9006153 | Jun 1990 | WO |
9008571 | Aug 1990 | WO |
9303790 | Mar 1993 | WO |
Number | Date | Country | |
---|---|---|---|
20040039328 A1 | Feb 2004 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 09153640 | Sep 1998 | US |
Child | 09653992 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 09653992 | Sep 2000 | US |
Child | 10647295 | US |